Biomedical Research

Objective: To investigate clinical efficacy and safety of novorapid flexpen in treatment of gestational diabetes mellitus.

Methods: From January 2016 to May 2017, total 71 gestational diabetes patients enrolled in our hospital was selected as the research objects. All patients were randomly divided into observation group (n=36) and control group (n=35). In the control group, patients received routine treatment while patients in the observation group were given novorapid flexpen. The blood glucose level, clinical efficacy, adverse pregnancy outcome and incidence of hypoglycemia were analyzed and compared between those two groups.

Results: There was significant difference between patients in different groups in the blood glucose level, clinical efficacy and the incidence of hypoglycemia. The adverse pregnancy outcome of the observation group was obviously less than that of the control group, P<0.05.

Conclusion: Novorapid flexpen is effective and safe in treatment of gestational diabetes mellitus, thus worth clinical application.

Author(s): Jinping Jia, Jiahan Wu, Yingjun Wu, Ling Hu
Abstract | Full-Text | PDF

Share this